Based on the key indicators related to Madrigal Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Madrigal Pharmaceuticals may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Madrigal Pharmaceuticals' Other Stockholder Equity is quite stable compared to the past year. Total Liabilities is expected to rise to about 302.3 M this year, although the value of Net Debt will most likely fall to (104 M). Key indicators impacting Madrigal Pharmaceuticals' financial strength include:
The financial analysis of Madrigal Pharmaceuticals is a critical element in measuring its lifeblood. Investors should not minimize Madrigal Pharmaceuticals' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Madrigal Pharmaceuticals competes with TG Therapeutics, Terns Pharmaceuticals, Hepion Pharmaceuticals, Viking Therapeutics, and Sarepta Therapeutics. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania. Madrigal Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 71 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Madrigal Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Madrigal Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Madrigal Pharmaceuticals competition to find correlations between indicators driving Madrigal Pharmaceuticals's intrinsic value. More Info.
Madrigal Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Madrigal Pharmaceuticals' Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Madrigal Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Madrigal Pharmaceuticals Systematic Risk
Madrigal Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Madrigal Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Madrigal Pharmaceuticals correlated with the market. If Beta is less than 0 Madrigal Pharmaceuticals generally moves in the opposite direction as compared to the market. If Madrigal Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Madrigal Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Madrigal Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Madrigal Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Madrigal Pharmaceuticals Thematic Clasifications
Madrigal Pharmaceuticals is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Madrigal Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Madrigal Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Madrigal Pharmaceuticals growth as a starting point in their analysis.
Madrigal Pharmaceuticals March 25, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Madrigal Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Madrigal Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Madrigal Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Madrigal Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Madrigal Pharmaceuticals's daily price indicators and compare them against related drivers.
When determining whether Madrigal Pharmaceuticals is a strong investment it is important to analyze Madrigal Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Madrigal Pharmaceuticals' future performance. For an informed investment choice regarding Madrigal Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(21.90)
Revenue Per Share
8.468
Return On Assets
(0.37)
Return On Equity
(0.80)
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.